hero image
Hu Yang, Ph.D. - VCU College of Engineering. hyang2@vcu.edu, 804-828-5459, Biotech 8, Room 418, 737 North 5th, Richmond, VA, US

Hu Yang, Ph.D. Hu Yang, Ph.D.

Qimonda Professor, Department of Chemical and Life Science Engineering | VCU College of Engineering

hyang2@vcu.edu, 804-828-5459, Biotech 8, Room 418, 737 North 5th, Richmond, VA, UNITED STATES

Dr. Yang's research is the convergence of materials science and translational medicine.



Grant reviewer for NIH and NSF;
Editorial Board, Journal of Biological Engineering;
Editorial Board, International Journal of Polymeric Materials and Polymeric Biomaterials

Industry Expertise (5)

Research Education/Learning Chemicals Nanotechnology Pharmaceuticals

Areas of Expertise (20)

atherosclerosis Glaucoma Nano-Biotechnology Click chemistry Bioorthogonal chemistry Central nervous system trauma and diseases Head and Neck Cancers Ocular Biomaterials Translational Research Smart polymeric materials and structures Nanoscience and nanotechnology Nanoparticles Gene Therapy Drug Delivery Dendrimer Cancer Research Tissue Engineering Biomaterials Polymer Characterization and Processing Translational Medicine

Accomplishments (3)

Qimonda Professorship (professional)

Awarded by Qimonda.

NSF Career Award (professional)

Awarded by the National Science Foundation.

Wallace Coulter Foundation Translational Research Award (professional)

Awarded by the Wallace H. Coulter Foundation.

Education (3)

University of Wisconsin-Madison: Postdoc, Pharmaceutical Sciences 2005

University of Akron: Ph.D., Chemical Engineering 2004

Sichuan University: B.E., Polymer 1998

Affiliations (5)

  • Department of Chemical and Life Science Engineering (primary)
  • Department of Pharmaceutics (joint)
  • Department of Biomedical Engineering (courtesy)
  • Massey Cancer Center
  • Society for Biomaterials

Patents (1)

Clickable polyoxetane carrier for drug delivery



The present application relates to polyoxetanes, compositions containing same, methods of making, and their use.

view more

Selected Articles (3)

Folic Acid-Decorated Polyamidoamine Dendrimer Exhibits High Tumor Uptake and Sustained Highly Localized Retention in Solid Tumors: Its Utility for Local siRNA Delivery Acta Biomater.

The utility of folic acid (FA)-decorated polyamidoamine dendrimer G4 (G4-FA) as a vector was investigated for local delivery of siRNA. In a xenograft HN12 (or HN12-YFP) tumor mouse model of head and neck squamous cell carcinomas (HNSCC), intratumorally (i.t.) injected G4-FA exhibited high tumor uptake and sustained highly localized retention in the tumors according to near infrared (NIR) imaging assessment. siRNA against vascular endothelial growth factor A (siVEGFA) was chosen as a therapeutic modality. Compared to the nontherapeutic treatment groups (PBS solution or dendrimer complexed with nontherapeutic green fluorescent protein siRNA [siGFP]), G4-FA/siVEGFA showed tumor inhibition effects in single-dose and two-dose regimen studies. In particular, two doses of G4-FA/siVEGFA i.t. administered eight days apart resulted in a more profound inhibition of tumor growth, accompanied with significant reduction in angiogenesis, as judged by CD31 staining and microvessel counts. Tumor size reduction in the two-dose regimen study was ascertained semi-quantitatively by live fluorescence imaging of YFP tumors and independently supported antitumor effects of G4-FA/siVEGFA. Taken together, G4-FA shows high tumor uptake and sustained retention properties, making i

view more

Targeted nanosystems: Advances in targeted dendrimers for cancer therapy, Nanomedicine: Nanotechnology, Biology and Medicine


Dendrimers possess discrete highly compact nanostructures constituted of successive branched layers. Soon after the inception of dendrimers, recognition of their tunable structures and biologically favorable properties provoked a great enthusiasm in delving deeply into the utility of dendrimers for biomedical and pharmaceutical applications. One of the most important nanotechnology applications is the development of nanomedicines for targeted cancer therapies. Tremendous success in targeted therapies has been achieved with the use of dendrimer-based nanomedicines. This article provides a concise review on latest advances in the utility of dendrimers in immunotherapies and hormone therapies.

view more

Dendrimer-enabled transformation of Anaplasma phagocytophilum, Microbes and Infection


Anaplasma phagocytophilum is an obligate intracellular bacterium that causes the emerging infection, granulocytic anaplasmosis. While electroporation can transform A. phagocytophilum isolated from host cells, no method has been developed to transform it while growing inside the ApV (A. phagocytophilum-occupied vacuole). Polyamidoamine (PAMAM) dendrimers, well-defined tree-branched macromolecules used for gene therapy and nucleic acid delivery into mammalian cells, were recently shown to be effective in transforming Chlamydia spp. actively growing in host cells. We determined if we could adapt a similar system to transform A. phagocytophilum. Incubating fluorescently labeled PAMAM dendrimers with infected host cells resulted in fluorescein-positive ApVs. Incubating infected host cells or host cell-free A. phagocytophilum organisms with dendrimers complexed with pCis GFPuv-SS Himar A7 plasmid, which carries a Himar1 transposon cassette encoding GFPuv and spectinomycin/streptomycin resistance plus the Himar1 transposase itself, resulted in GFP-positive, antibiotic resistant bacteria. Yet, transformation efficiencies were low. The transformed bacterial populations could only be maintained for a few passages, likely due to random Himar1 cassette-mediated disruption of A. phagocytophilum genes required for fitness. Nonetheless, these results provide proof of principle that dendrimers can deliver exogenous DNA into A. phagocytophilum, both inside and outside of host cells.

view more